Losartan recall: FDA says more blood pressure medicine has cancer risk

More blood pressure medicines recalled over possible cancer-causing impurity


Ryan W. Miller


USA TODAY
Published 2:49 PM EDT Sep 23, 2019

A recall of common blood pressure medication losartan has been expanded for a fifth time after manufacturer Torrent Pharmaceuticals found a possibly carcinogenic impurity in more batches of the drug, federal health officials said.

Three additional lots of losartan potassium tablets and two additional lots of losartan potassium/hydrochlorothiazide tablets were under recall, the U.S. Food and Drug Administration said Thursday.

The lots contained levels of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) above the acceptable daily intake levels determined by the FDA. NMBA is a “potential human carcinogen,” the FDA says. 

The recall comes amid a larger string of recalls of blood pressure medications valsartan, losartan and irbesartan that contain trace levels of carcinogens NMBA, N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA), the FDA says.

Hundreds of lots of the medication have been recalled since last July.

The drugs, angiotensin II receptor blockers (ARBs), work by widening or relaxing blood vessels, thus lowering blood pressure. However, not all ARBs have been affected, and patients should continue to use their medication, the FDA says.

Heartburn drugs: FDA finds probable carcinogen in Zantac and other heartburn drugs

“The risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment,” federal health officials wrote in a statement.

The FDA has said the contaminants likely resulted from a manufacturing change adopted by factories in China and India that make the drug ingredients. The manufacturing change may generate the contaminants “when specific chemicals and reaction conditions are present” and can result of reusing materials such as solvents.

In January, the agency admitted that some versions of the drug valsartan contained trace amounts of a carcinogen for four years before regulators detected the impurity last summer.

New generic: FDA approves new valsartan generic to counter shortages of the blood pressure drug

However, FDA officials said the cancer risk for any person who took valsartan that had the carcinogen N-nitrosodimethylamine, or NDMA, is small. FDA scientists concluded there would be one more cancer case above average rates for every 8,000 people on the highest dose of valsartan for four years. 

Contributing: Ken Alltucker. Follow USA TODAY’s Ryan Miller on Twitter @RyanW_Miller

This content was originally published here.

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Type 2 Diabetes

Losartan recall: FDA says more blood pressure medicine has cancer risk

More blood pressure medicines recalled over possible cancer-causing impurity Ryan W. Miller USA TODAY Published 2:49 PM EDT Sep 23, 2019 A recall of common blood pressure medication losartan has been expanded for a fifth time after manufacturer Torrent Pharmaceuticals found a possibly carcinogenic impurity in more batches of the drug, federal health officials said. Three additional lots of losartan potassium

Keto Diet

It takes 21 litres of water to produce a small chocolate bar. How water-wise is your diet?

A small chocolate bar takes 21 litres of water to produce. Byline: CAROLINE BLUMBERG/ EPA Our diets can have a big environmental impact. The greenhouse gas emissions involved in producing and transporting various foods has been well researched, but have you ever thought about the water-scarcity impacts of producing your favourite foods? The answers may surprise you. In research recently

Do You Want To Boost Your Business?

drop us a line and keep in touch